Organization
University College London Hospitals, NHS Foundation Trust
1 abstract
Abstract
Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.Org: University College London Hospitals, NHS Foundation Trust, Hematología Hospital 12 de Octubre,